Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Graphene-infused pillow ODM Taiwan

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.China anti-bacterial pillow ODM design

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Thailand ODM expert for comfort products

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Indonesia sustainable material ODM solutions

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Thailand graphene product OEM service

Research indicates alternative splicing is key in regulating gene expression by producing and degrading unproductive transcripts, offering new insights into gene silencing and potential therapeutic approaches. New research from the University of Chicago reveals that alternative splicing plays a much bigger role than expected in controlling gene expression. This process produces high rates of unproductive transcripts, which are promptly degraded. These findings suggest that unproductive splicing could control gene silencing and has implications for treating diseases by manipulating these mechanisms. Alternative splicing is a genetic process where different segments of genes are removed, and the remaining pieces are joined together during transcription to messenger RNA (mRNA). This mechanism increases the diversity of proteins that can be generated from genes, by assembling sections of genetic code into different combinations. This is believed to enhance biological complexity by allowing genes to produce different versions of proteins, or protein isoforms, for many different uses. New research from the University of Chicago suggests that alternative splicing may have an even greater influence on biology than just by creating new protein isoforms. The study, published this week in Nature Genetics, shows that the biggest impact of alternative splicing may come via its role in regulating gene expression levels. Unproductive Transcripts and Gene Regulation The research team, led by Yang Li, PhD, Benjamin Fair, PhD, and Carlos Buen Abad Najar, PhD, analyzed large sets of genomic data, covering various stages from early transcription to when RNA transcripts are destroyed by the cell. They saw that cells produced three times as many “unproductive” transcripts—RNA molecules with mistakes or unexpected configurations—as when they analyzed steady-state, finished RNA only. Unproductive transcripts are quickly destroyed by a cellular process called nonsense-mediated decay (NMD). Li’s team calculated that on average, about 15% of transcripts that are started are almost immediately degraded by NMD; when they looked at genes with low expression levels, that number went up to 50%. Purpose of High Error Rates in Transcription “We thought that was a huge breakthrough,” said Li, who is an Associate Professor of Medicine and Human Genetics. “It already seems wasteful to degrade 15% of mRNA transcripts, but no one would have thought that the cell is transcribing so much and getting rid of the errors immediately, seemingly without any purpose.” Why would the cell fire up its genetic production machinery to immediately trash 15 to 50% of its output? And why would transcription make so many mistakes in the first place? “We think it’s because NMD is so efficient,” Li said. “The cell can afford to make mistakes without damaging things, so there’s no selective pressure to make fewer mistakes.” Genetic Variability and Expression Levels But Li suspected there must also be some purpose for such a widespread phenomenon. His team conducted a genome-wide association study (GWAS) to compare gene expression levels across different cell lines. They found many variations at genetic locations that are known to affect the level of unproductive splicing. These loci were just as often associated with differences in genetic expression caused by NMD as they were with differences in production of multiple protein isoforms. Li believes cells sometimes purposely select transcripts doomed for NMD to decrease expression levels. If the nascent RNA is destroyed before it gets fully transcribed, it will never produce proteins to execute biological functions. This effectively silences the genes, like deleting an email draft before its writer can press send. “We found that genetic variations that increase unproductive splicing often decreased gene expression levels,” Li said. “This shows that there this mechanism must have some effect on expression, because it is so widespread.” Implications for Disease and Drug Development The team found that many variants linked to complex diseases are also associated with more unproductive splicing and decreased gene expression. So, they believe that a better understanding of its impact could help develop new treatments that leverage the alternative splicing-NMD process. Drug molecules could be designed to decrease the amount of unproductive splicing, and thus increase gene expression. One approved drug for spinal muscular atrophy already takes this approach to restore proteins that are being shut off. Another approach could be to increase the NMD process to decrease expression, for example in rampant cancer genes. “We think we can target a lot of genes because now we know how much this process is going on,” Li said. “People used to think that alternative splicing was mainly a way to make an organism more complex by generating different versions of proteins. Now we’re showing that it might not be its most important function. It could be simply to control gene expression.” Reference: “Global impact of unproductive splicing on human gene expression” by Benjamin Fair, Carlos F. Buen Abad Najar, Junxing Zhao, Stephanie Lozano, Austin Reilly, Gabriela Mossian, Jonathan P. Staley, Jingxin Wang and Yang I. Li, 2 September 2024, Nature Genetics. DOI: 10.1038/s41588-024-01872-x The study was supported by funding from the National Institutes of Health (grants R01GM130738, R01HG011067, and R35GM147498), a GREGoR Consortium Grant and the W. M. Keck Foundation. Additional authors include Junxing Zhao, Austin Reilly, Gabriela Mossian, Jonathan P Staley, and Jingxin Wang from the University of Chicago, and Stephanie Lozano from the University of California, Davis.

University of Tokyo researchers have created a mathematical framework for cellular death, offering new tools to study and potentially control life-death transitions in biological systems. Researchers are redefining the criteria that determine whether a cell is considered alive or dead. Cellular death is a fundamental concept in biological sciences. Despite its importance, its definition varies depending on the context in which it occurs and lacks a general mathematical definition. Researchers from the University of Tokyo propose a new mathematical definition of death based on whether a potentially dead cell can return to a predefined “representative state of living,” which are the states of being that we can confidently call “alive.” The researchers’ work could be useful for biological researchers and future medical research. While it’s not something we like to think about, death comes for us all eventually, whether you’re an animal, a plant, or even a cell. And even though we can all differentiate between what is alive and dead, it might be surprising to know that death at a cellular level lacks a widely recognized mathematical definition. An overview of the researchers’ ideas. Credit: 2024 Illustration by Ivana Duic Urushibata. CC-BY-ND Given that cell death plays such an important role in various biological processes and can have important health implications, it’s of critical importance to understand what we really mean by cellular death, especially in research. A Mathematical Approach to the Life-Death Boundary “My long-term scientific goal is to understand the inherent difference between life and nonlife, mathematically; why the transition from nonlife to life is so difficult, while the other way around is so easy,” said Assistant Professor Yusuke Himeoka from the Universal Biology Institute. “Our aim in this project was to develop a mathematical definition and computational method to quantify the life-death boundary. We were able to do this by exploiting an important feature of biological reaction systems, specifically enzymatic reactions within cells.” There’s a thin line between the living and the dead, and for cells, it depends on whether chemical processes that shut down can be returned to their active states. Credit: 2024 Illustration by Ivana Duic Urushibata. CC-BY-ND Himeoka and his team proposed a mathematical definition of cell death. It’s based on the way cellular states including metabolism can be controlled by modulating the activities of enzymes. They define dead states as those states from which cells cannot return to an apparent “living” state, regardless of the modulation of any biochemical processes. This led them to develop a computational method for quantifying the life-death boundary, which they call “stoichiometric rays.” The method was developed by focusing on enzymatic reactions and the second law of thermodynamics, which states that systems naturally move from ordered to disordered states. Researchers could use these methods to better understand, control, and possibly even reverse, cellular death in controlled lab experiments. “This method of computation is not applicable to autonomic systems, however, the systems which make the machinery for control, such as proteins. Autonomy is one of the hallmarks of living systems. I would like to extend our method so that it can also be applied to these,” said Himeoka. “We naively believe that death is irreversible, but it is not so trivial and does not have to be the case. I believe that should death become more under our control, human beings, our understanding of life, and society will change completely. In this sense, understanding death is crucial in terms of science and social implications.” Reference: “Theoretical basis for cell deaths” by Yusuke Himeoka, Shuhei A. Horiguchi and Tetsuya J. Kobayashi, 27 November 2024, Physical Review Research. DOI: 10.1103/PhysRevResearch.6.043217

Sections of the fetus and placenta. Credit: Ionel Sandovici Cambridge scientists have identified a key signal that the fetus uses to control its supply of nutrients from the placenta, revealing a tug-of-war between genes inherited from the father and from the mother. The study, carried out in mice, could help explain why some babies grow poorly in the womb. As the fetus grows, it needs to communicate its increasing needs for food to the mother. It receives its nourishment via blood vessels in the placenta, a specialized organ that contains cells from both baby and mother. Between 10% and 15% of babies grow poorly in the womb, often showing reduced growth of blood vessels in the placenta. In humans, these blood vessels expand dramatically between mid and late gestation, reaching a total length of approximately 320 kilometers at term. In a study published today (December 27, 2021) in Developmental Cell, a team led by scientists at the University of Cambridge used genetically engineered mice to show how the fetus produces a signal to encourage growth of blood vessels within the placenta. This signal also causes modifications to other cells of the placenta to allow for more nutrients from the mother to go through to the fetus. Dr. Ionel Sandovici, the paper’s first author, said: “As it grows in the womb, the fetus needs food from its mum, and healthy blood vessels in the placenta are essential to help it get the correct amount of nutrients it needs. “We’ve identified one way that the fetus uses to communicate with the placenta to prompt the correct expansion of these blood vessels. When this communication breaks down, the blood vessels don’t develop properly and the baby will struggle to get all the food it needs.” The team found that the fetus sends a signal known as IGF2 that reaches the placenta through the umbilical cord. In humans, levels of IGF2 in the umbilical cord progressively increase between 29 weeks of gestation and term: too much IGF2 is associated with too much growth, while not enough IGF2 is associated with too little growth. Babies that are too large or too small are more likely to suffer or even die at birth, and have a higher risk of developing diabetes and heart problems as adults. Dr. Sandovici added: “We’ve known for some time that IGF2 promotes the growth of the organs where it is produced. In this study, we’ve shown that IGF2 also acts like a classical hormone – it’s produced by the fetus, goes into the fetal blood, through the umbilical cord and to the placenta, where it acts.” Particularly interesting is what their findings reveal about the tussle taking place in the womb. In mice, the response to IGF2 in the blood vessels of the placenta is mediated by another protein, called IGF2R. The two genes that produce IGF2 and IGF2R are ‘imprinted’ – a process by which molecular switches on the genes identify their parental origin and can turn the genes on or off. In this case, only the copy of the igf2 gene inherited from the father is active, while only the copy of igf2r inherited from the mother is active. Lead author Dr. Miguel Constância, said: “One theory about imprinted genes is that paternally-expressed genes are greedy and selfish. They want to extract the most resources as possible from the mother. But maternally-expressed genes act as countermeasures to balance these demands.” “In our study, the father’s gene drives the fetus’s demands for larger blood vessels and more nutrients, while the mother’s gene in the placenta tries to control how much nourishment she provides. There’s a tug-of-war taking place, a battle of the sexes at the level of the genome.” The team say their findings will allow a better understanding of how the fetus, placenta, and mother communicate with each other during pregnancy. This in turn could lead to ways of measuring levels of IGF2 in the fetus and finding ways to use medication to normalize these levels or promote normal development of placental vasculature. The researchers used mice, as it is possible to manipulate their genes to mimic different developmental conditions. This enables them to study in detail the different mechanisms taking place. The physiology and biology of mice have many similarities with those of humans, allowing researchers to model human pregnancy, in order to understand it better. Reference: “The Imprinted Igf2-Igf2r Axis is Critical for Matching Placental Microvasculature Expansion to Fetal Growth” by Ionel Sandovici, Aikaterini Georgopoulou, Vicente Pérez-García, Antonia Hufnagel, Jorge López-Tello, Brian Y.H.Lam, Samira N.Schiefer, Chelsea Gaudreau, Fátima Santos, Katharina Hoelle, Giles S.H.Yeo, Keith Burling, Moritz Reiterer, Abigail L.Fowden, Graham J.Burton, Cristina M.Branco, Amanda N.Sferruzzi-Perri and Miguel Constância, 27 December 2021, Developmental Cell. DOI: 10.1016/j.devcel.2021.12.005 The lead researchers are based at the Department of Obstetrics and Gynaecology, the Medical Research Council Metabolic Diseases Unit, part of the Wellcome-MRC Institute of Metabolic Science, and the Centre for Trophoblast Research, all at the University of Cambridge. The research was largely funded by the Biotechnology and Biological Sciences Research Council, Medical Research Council, Wellcome Trust and Centre for Trophoblast Research.

DVDV1551RTWW78V